Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,975 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study.
Wang S, Chao J, Wang H, Li S, Wang Y, Zhu C, Zhang N, Piao M, Yang X, Liu K, Xun Z, Sang X, Yang X, Duan W, Zhao H. Wang S, et al. Among authors: liu k. Cancer Immunol Immunother. 2024 Oct 3;73(12):249. doi: 10.1007/s00262-024-03841-z. Cancer Immunol Immunother. 2024. PMID: 39358645 Free PMC article.
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Wang S, Wang Y, Zhu C, Liu K, Chao J, Zhang N, Piao M, Yang X, Zhang L, Long J, Xun Z, Zhang T, Sang X, Yang X, Zhao H. Wang S, et al. Among authors: liu k. Int J Surg. 2024 Aug 1;110(8):4608-4616. doi: 10.1097/JS9.0000000000001540. Int J Surg. 2024. PMID: 38704621 Free PMC article.
Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
Tan Y, Liu K, Zhu C, Wang S, Wang Y, Xue J, Ning C, Zhang N, Chao J, Zhang L, Long J, Yang X, Zeng D, Zhao L, Zhao H. Tan Y, et al. Among authors: liu k. Cancer Immunol Immunother. 2024 Oct 3;73(12):240. doi: 10.1007/s00262-024-03831-1. Cancer Immunol Immunother. 2024. PMID: 39358463 Free PMC article.
Mesenchymal stem cell therapy for severe COVID-19.
Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, Li T, Hu W, Zhen C, Wang FS. Shi L, et al. Among authors: liu k. Signal Transduct Target Ther. 2021 Sep 8;6(1):339. doi: 10.1038/s41392-021-00754-6. Signal Transduct Target Ther. 2021. PMID: 34497264 Free PMC article. Review.
25,975 results
You have reached the last available page of results. Please see the User Guide for more information.